Rezolute (RZLT) | Stock Overview & Key Data
Rezolute Performance Comparison
Stock Range
Today's Range
Low: $7.26
High: $8.23
on September 18, 2025
52 Week Range
Low: $2.21
High: $8.34
on April 7, 2025
on September 10, 2025
All-Time High: $750.00 on January 21, 2013
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$671.6M
EPS
-1.16
P/E Ratio (TTM)
-5.80
Forward P/E
-5.75
P/B Ratio
5.48
PEG Ratio
0.28
Div. Yield
N/A
ROE
-95.16%
Beta
0.033
Debt to Equity
2.15
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-52.85%
Return on Equity (TTM)
-95.16%
EBITDA
$-77.1M
Net Income (TTM)
$-73.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Rezolute RZLT | 671.61M Small-cap | 2.89% | 25.19% | 101.47% | 143.32% | 59.22% | 61.42% | 190.78% | -63.56% |
| Vertex VRTX | 100.34B Large-cap | -2.58% | -0.71% | -13.67% | -24.43% | -4.60% | -16.74% | 36.57% | 44.35% |
| Regeneron REGN | 60.95B Large-cap | 5.37% | 4.32% | 16.58% | -9.96% | -16.29% | -47.71% | -14.14% | 4.29% |
| Adaptive ADPT | 1.92B Small-cap | 2.08% | 10.96% | 31.52% | 87.35% | 122.46% | 196.13% | 111.85% | -71.48% |
| Sarepta Therapeutics SRPT | 1.89B Small-cap | 3.41% | -11.77% | -10.83% | -74.82% | -85.08% | -85.44% | -82.88% | -87.14% |
| Dyne Therapeutics DYN | 1.87B Small-cap | 5.61% | 12.90% | 29.13% | 10.65% | -45.33% | -61.96% | 12.17% | -36.73% |
Ownership & Short Interest
Insider Ownership
9.68%
Institutional Ownership
90.03%
Shares Short
7M
Short Ratio
10.44
Short % of Shares Outstanding
10.36%
Average 10-Day Volume
846K
Average 90-Day Volume
768K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is RZLT's 52-week high and low?
- In the last 52 weeks, Rezolute reached a high of $8.34 (on September 10, 2025) and a low of $2.21 (on April 7, 2025).
- What is the market cap and P/E ratio for RZLT?
- Curious about Rezolute's size and valuation? Its market capitalization stands at 671.61M. When it comes to valuation, the P/E ratio (trailing twelve months) is -5.80, and the forward P/E (looking ahead) is -5.75.
- Does RZLT pay dividends? If so, what's the yield?
- As for dividends, Rezolute isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Rezolute's main competitors or similar companies to consider before investing?
When looking at Rezolute, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.34B Healthcare Biotechnology -16.74% 36.57% Regeneron
REGN60.95B Healthcare Biotechnology -47.71% -14.14% Adaptive
ADPT1.92B Healthcare Biotechnology 196.13% 111.85% Sarepta Therapeutics
SRPT1.89B Healthcare Biotechnology -85.44% -82.88% Dyne Therapeutics
DYN1.87B Healthcare Biotechnology -61.96% 12.17% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Rezolute, Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Rezolute's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -95.16%, the Debt to Equity ratio from the most recent quarter is 2.15, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for RZLT?
- Looking at Rezolute's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of RZLT stock is held by insiders and institutions?
- Wondering who owns Rezolute stock? Company insiders (like executives and directors) hold about 9.68% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 90.03%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.